Bayer AG Sponsored ADR (BAYRY)
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
Best Value Stocks to Buy for July 10th
BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer , according to results from a late-stage trial.
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
What Makes Bayer (BAYRY) a New Buy Stock
Bayer (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.
Airlines must ink long-term deals on greener fuels to boost volumes: Bayer exec
Airlines need to reach long-term agreements to buy bigger quantities of sustainable aviation fuel if they want to boost global volumes of the lower-emission fuel required for industry climate targets, a Bayer executive said on Tuesday.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
Bayer A.G.'s stock is very cheap and near multi-year lows, but ongoing declines and uncertain turnaround make it risky for conservative investors. Pharmaceuticals and consumer health divisions are showing rising sales, while crop science is under pressure and facing regulatory risks, especially with glyphosate. Recent earnings disappointed, with declining profitability and net losses, but operational cash flow has improved, and sales remain stable.
